Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

265
Delayed Quote. Delayed Euronext Alternext - 04/17 11:35:00 am
2.71 EUR   -0.73%
04/07 NEOVACS : Completes Enrollment for Phase IIB of TNF-Kinoid in Rheumatoid Ar..
03/27 NEOVACS : Financial results for 2013
03/27 NEOVACS : Financial Results for 2013
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
04/11/2014 04/14/2014 04/15/2014 04/16/2014 04/17/2014 Date
3.1(c) 2.83(c) 2.69(c) 2.73(c) 2.71(c) Last
168 094 401 569 109 280 183 613 120 086 Volume
-2.82% -8.71% -4.95% +1.49% -0.73% Change
More quotes
Company
Neovacs SA is a biotechnology company. It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer. It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid. The Tumor Necrosis... 
Sector
Biotechnology
Calendar
-
Surperformance© rating of NEOVACS
Trading Rating : Investor Rating :
More about the company
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2013 0,00 M
EBIT 2013 -7,94 M
Net income 2013 -6,78 M
Finance 2013 2,01 M
Yield 2013 -
Sales 2014 0,33 M
EBIT 2014 -8,89 M
Net income 2014 -7,55 M
Debt 2014 1,09 M
Yield 2014 -
PER 2013 -
PER 2014
EV / Sales 2013 15 696x
EV / Sales 2014 165x
Capitalization 53,8 M
More Financials
Latest news on NEOVACS
04/07 NEOVACS : Completes Enrollment for Phase IIB of TNF-Kinoid in Rheumatoid Arthrit..
03/27 NEOVACS : Financial results for 2013
03/27 NEOVACS : Financial Results for 2013
03/12 NEOVACS : announces positive iDSMB review of the phase IIb study of TNF-Kinoid i..
03/12 NEOVACS : Announces Positive iDSMB Review of the Phase IIb Study of TNF-Kinoid i..
02/25 NEOVACS : Strengthens Its Expertise in Four Therapeutic Areas
01/08 NEOVACS : Half-Year Report on the Liquidity Contract
2013 NEOVACS : Secures a Contingent Equity Line
2013 NEOVACS : First patients enrolled in Phase IIb study of TNF-Kinoid for Rheumatoi..
2013 NEOVACS : Recrutement des premiers patients de l’étude de Phase IIb du TNF-Kinoï..
2013 NEOVACS : Succesfully Enrolls First Patients in Its Phase IIb Study of TNF-Kinoi..
2013 NEOVACS : Professor Boissier, Member of the Scientific Board of Neovacs, Present..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
NEOVACS : Income Statement Evolution
More Financials
EPS Revisions
NEOVACS : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF